Cabazitaxel 60mg per 1.5ml injection
Cabazitaxel 60mg per 1.5ml injection is an antineoplastic agent which is used for the treatment of cancer cells. It comes under the brand name of Jevtana. It belongs to the category of taxane class of intravenous use.
The jevtana injection is prepared by semi-synthesis with a precursor element extracted from the yew needles.
Some interactive reactions are observed with concomitant drugs such as itraconazole, atazanavir, ketoconazole, ritonavir, voriconazole, saquinavir, nefazodone. These interactions may increase plasma concentrations of active ingredient Cabazitaxel. Hence, it is advised not to co-administer such drugs with this product or injection.
1. What is Jevtana?
Jevtana is the brand name for cabazitaxel, an anti-cancer medicine belonging to the taxane class. It is supplied as an intravenous infusion concentrate and is used in oncology treatment under specialist medical supervision. Lotus International lists Jevtana as Cabazitaxel 60 mg/1.5 ml injection.
2. What is Jevtana used for?
Jevtana is used to treat metastatic castration-resistant prostate cancer (mCRPC) in men whose disease has progressed following previous treatment. In the European indication, it is used in combination with prednisone or prednisolone in patients previously treated with docetaxel.
3. How does Jevtana (cabazitaxel) work?
Cabazitaxel is a microtubule inhibitor that interferes with microtubule function required for cell division. This mechanism helps inhibit the growth and multiplication of cancer cells.
4. What strength of Jevtana is available?
Jevtana is supplied as a 60 mg/1.5 mL injection concentrate. The product is supplied with a diluent and requires preparation before intravenous administration.
5. How is Jevtana administered?
Jevtana is administered by intravenous infusion after appropriate dilution and preparation by qualified healthcare professionals. The U.S. prescribing information specifies administration as a one-hour IV infusion, while the treatment schedule and dose are determined by the prescribing oncologist according to the applicable product information.